Psycheceutical Announces Julian Bailes, M.D. as Principal Medical Advisor

MIAMI, March 1, 2022 /PRNewswire/ -- Psycheceutical, Inc. (a wholly-owned subsidiary of Blue Water Ventures International, Inc. BWVI, a bioscience company dedicated to the development and commercialization of psychedelic medicines, today announced the addition of Dr. Julian Bailes as Principal Medical Advisor. Bailes will participate in the strategy, direction, and execution of the company's clinical and technology development in pursuit of its mission to accelerate the research, availability, and delivery of safe and effective psychedelic pharmaceutical medicines.

Bailes is a recognized leader in the field of neurosurgery and the impact of brain injury on brain function. His expertise in the field of chronic traumatic encephalopathy (CTE) is showcased in the 2015 film "Concussion," starring Will Smith, where Bailes is portrayed by actor Alec Baldwin. CTE is a progressive degenerative disease found in individuals who have sustained repetitive head impacts, multiple concussions or other forms of head injury. His expertise includes cranial surgery, traumatic brain injury, PTSD, and CTE.

Bailes is the chairman of the Department of Neurosurgery at the NorthShore University Health System and co-director of the NorthShore Neurological Institute, both located in Evanston, Ill. He also serves as Chairman of the Pop Warner Football Medical Advisory Committee. As Principal Medical Advisor for Psycheceutical, Bailes will be a key advisor to both the senior management team and the board of directors, which determine and oversee the company's drug development activities.

"Dr. Bailes brings critical knowledge of the central nervous system and a shared mission of making vital psychedelic therapies available to the people who need them as quickly and safely as possible," said Chad Harman, CEO, Psycheceutical. "His depth of knowledge and proven leadership track record will be essential to bringing our patented psychedelic delivery technologies to market and, ultimately, strengthening the broader psychedelic pharmaceutical industry as a whole."

With more than 300 scientific publications concerning various aspects of neurosurgery and editorial assignments for a number of medical journals, Dr. Bailes' reputation in the field of neurosurgery will bring further academic expertise to the emerging field of psychedelic medicine.

"The psychedelic pharmaceutical industry is primed for technological improvements in how these powerful medicines are developed and delivered to patients," commented Dr. Bailes. "I am excited to be working with a company at the forefront of helping bring these products to market in a safe, efficient way."

About Psycheceutical, Inc.

Psycheceutical, Inc. is the wholly-owned subsidiary of Blue Water Ventures International, Inc. BWVI. Psycheceutical is developing cutting-edge delivery technologies to support safe and effective psychedelic pharmaceutical medicines. Powered by a team with more than 100 years' combined experience in development, regulatory approval processes, and commercialization across the pharmaceutical industry, Psycheceutical is on a mission to bring safety and efficacy to psychedelic compounds. Learn more at Psycheceutical.com.

Forward-Looking Statements:

Certain statements in this news release related to the Company constitute "forward-looking information" within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These uncertainties include, but are not limited to, (i) general market growth for and acceptance of psychedelic-inspired medicines, (ii) capital and credit availability and market volatility, (iii) general economic conditions, (iv) governmental approvals and compliance with regulations, (v) product research and development and clinical trial risks, (vi) incorrect underlying assumptions, and (vii) our future business development, results of operations, and financial condition. These statements generally can be identified using forward-looking words such as "will," "may," "should," "could," "intend," "estimate," "plan," "anticipate," "expect," "believe," "potential" or "continue," or the negative thereof or similar variations. All information provided in this press release is as of the date of this press release, and we undertake no duty to update such information, except as required under applicable law.   

Contact: 
Dianne Gleason 
highmountaincomms@gmail.com

SOURCE Psycheceutical, Inc.